These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 32404176)

  • 1. Anticancer drug R&D landscape in China.
    Zhao S; Zhao H; Lv C; Gong J; Zhang J; Fang W; Li J; Hu X; Ba Y; Xu B; Zhang Y; Fan Y; Li K; Chen X; Yang Z; Shen L; Zhang L
    J Hematol Oncol; 2020 May; 13(1):51. PubMed ID: 32404176
    [No Abstract]   [Full Text] [Related]  

  • 2. Challenges and Opportunities With Oncology Drug Development in China.
    Bajaj G; Gupta M; Wang HH; Barrett JS; Tan M; Rupalla K; Bertz R; Sheng J
    Clin Pharmacol Ther; 2019 Feb; 105(2):363-375. PubMed ID: 29328503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in clinical trials of cancer drugs in mainland China over the decade 2009-18: a systematic review.
    Li N; Huang HY; Wu DW; Yang ZM; Wang J; Wang JS; Wang SH; Fang H; Yu Y; Bai Y; Yan Z; Cao Y; Jiang M; Liu YF; Li KY; Xu BH; Sun Y; He J
    Lancet Oncol; 2019 Nov; 20(11):e619-e626. PubMed ID: 31674320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer drugs in China: affordability and creativity.
    The Lancet
    Lancet; 2018 May; 391(10133):1866. PubMed ID: 29781431
    [No Abstract]   [Full Text] [Related]  

  • 5. Bypassing phase 1 trials in the cancer drug development paradigm: generally unwise and potentially dangerous.
    Markman M
    Cancer; 2010 Nov; 116(22):5116-8. PubMed ID: 20665504
    [No Abstract]   [Full Text] [Related]  

  • 6. Phase 0 trials for anticancer drug development.
    Nat Rev Drug Discov; 2009 Jun; 8(6):442. PubMed ID: 19483703
    [No Abstract]   [Full Text] [Related]  

  • 7. Q&A: Geoffrey Shapiro on phase I drug trials. Spoke with Suzanne Rose.
    Shapiro G
    Cancer Discov; 2013 Oct; 3(10):1089. PubMed ID: 24124216
    [No Abstract]   [Full Text] [Related]  

  • 8. Facilitating patient-centered cancer research and a new era of drug discovery.
    Niederhuber JE
    Oncologist; 2009 Apr; 14(4):311-2. PubMed ID: 19365096
    [No Abstract]   [Full Text] [Related]  

  • 9. Challenges in anticancer drug R&D in China.
    Zhao S; Lv C; Gong J; Wenfeng F; Hu X; Ba Y; Xiaoyuan C; Zhimin Y; Shen L; Zhang L;
    Lancet Oncol; 2019 Feb; 20(2):183-186. PubMed ID: 30723039
    [No Abstract]   [Full Text] [Related]  

  • 10. Rapid advances in research on and development of anticancer drugs in China.
    Yao X; Du N; Hu S; Wang L; Gao J
    Biosci Trends; 2019 Nov; 13(5):461-463. PubMed ID: 31511442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?
    Carden CP; Sarker D; Postel-Vinay S; Yap TA; Attard G; Banerji U; Garrett MD; Thomas GV; Workman P; Kaye SB; de Bono JS
    Drug Discov Today; 2010 Feb; 15(3-4):88-97. PubMed ID: 19961955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel anticancer agents and targets: recent advances and future perspectives.
    Barot KP; Nikolova S; Ivanov I; Ghate MD
    Mini Rev Med Chem; 2013 Jul; 13(9):1239-55. PubMed ID: 23746058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanoparticle theories slowly turn into practice.
    Bender E
    Cancer Discov; 2011 Sep; 1(4):280. PubMed ID: 22586600
    [No Abstract]   [Full Text] [Related]  

  • 14. Factors influencing development of new therapeutics for oncology.
    Winquist RJ; Boucher DM
    Curr Opin Pharmacol; 2010 Aug; 10(4):353-5. PubMed ID: 20634136
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical trials and drug approvals continue to accelerate in China.
    Wang M
    Lancet Oncol; 2017 Jul; 18(7):855. PubMed ID: 28552212
    [No Abstract]   [Full Text] [Related]  

  • 16. Key drivers of biomedical innovation in cancer drug discovery.
    Huber MA; Kraut N
    EMBO Mol Med; 2015 Jan; 7(1):12-6. PubMed ID: 25422355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemical Biology as a Driver of Innovation in Cancer Research and Drug Discovery.
    Kostic M; Arkin M
    Cell Chem Biol; 2017 Sep; 24(9):1057. PubMed ID: 28938086
    [No Abstract]   [Full Text] [Related]  

  • 18. New regulatory framework for cancer drug development.
    Jones PS; Jones D
    Drug Discov Today; 2012 Mar; 17(5-6):227-31. PubMed ID: 22207222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticancer drug development: moving away from the old habits.
    Ades F; Zardavas D; Aftimos P; Awada A
    Curr Opin Oncol; 2014 May; 26(3):334-9. PubMed ID: 24614094
    [No Abstract]   [Full Text] [Related]  

  • 20. Review: new biological insights in early clinical studies.
    Maur M; Sessa C
    Hematol Oncol; 2007 Jun; 25(2):53-7. PubMed ID: 17351979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.